Very Favorable News Coverage Likely to Affect ResMed (NYSE:RMD) Stock Price
Media coverage about ResMed (NYSE:RMD) has been trending very positive this week, Accern Sentiment Analysis reports. The research firm scores the sentiment of press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ResMed earned a news sentiment score of 0.57 on Accern’s scale. Accern also assigned news coverage about the medical equipment provider an impact score of 66 out of 100, indicating that recent press coverage is likely to have an effect on the company’s share price in the next few days.
Here are some of the media stories that may have impacted Accern’s analysis:
- Boom or Bust? Is there any value in ResMed Inc. (NYSE:RMD) or Alexandria Real Estate Equities, Inc. (NYSE:ARE)? – FLBC News (flbcnews.com)
- Thermo Fisher Scientific Inc. (TMO) Analysts Remain Upbeat Despite -0.29% Loss (ibusinesslines.com)
- ResMed Inc. (NYSE:RMD) Closed 5.7% Above Its 50 Day Average (highlightpress.com)
- Trading Spotlight for Resmed Inc (RMD) – Wall Street Review (thewallstreetreview.com)
- ResMed Inc (RMD.AX) Shares Needle Moving -0.69% – Evergreen Caller (evergreencaller.com)
Shares of ResMed (RMD) opened at 77.59 on Monday. The company has a market capitalization of $11.00 billion, a P/E ratio of 34.03 and a beta of 0.84. ResMed has a 1-year low of $56.59 and a 1-year high of $79.44. The firm has a 50-day moving average of $72.98 and a 200 day moving average of $69.45.
ResMed (NYSE:RMD) last announced its quarterly earnings results on Thursday, April 27th. The medical equipment provider reported $0.71 EPS for the quarter, beating the Zacks’ consensus estimate of $0.70 by $0.01. ResMed had a return on equity of 22.53% and a net margin of 15.96%. The company had revenue of $514.20 million during the quarter, compared to analysts’ expectations of $525.84 million. During the same period in the prior year, the company earned $0.68 EPS. ResMed’s revenue was up 13.3% compared to the same quarter last year. On average, analysts anticipate that ResMed will post $2.80 EPS for the current year.
RMD has been the subject of several research reports. BidaskClub upgraded shares of ResMed from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. Zacks Investment Research lowered shares of ResMed from a “buy” rating to a “hold” rating in a research report on Tuesday, March 28th. Citigroup Inc. lowered shares of ResMed from a “buy” rating to a “neutral” rating in a research report on Friday, April 28th. William Blair reiterated an “outperform” rating on shares of ResMed in a research report on Thursday, April 13th. Finally, Jefferies Group LLC reiterated a “sell” rating and issued a $56.00 target price on shares of ResMed in a research report on Friday, April 28th. Four equities research analysts have rated the stock with a sell rating, four have given a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus target price of $64.50.
In related news, Director Peter C. Farrell sold 20,000 shares of the firm’s stock in a transaction on Wednesday, July 5th. The stock was sold at an average price of $76.50, for a total transaction of $1,530,000.00. Following the completion of the transaction, the director now directly owns 321,557 shares of the company’s stock, valued at approximately $24,599,110.50. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CFO Brett Sandercock sold 1,250 shares of the firm’s stock in a transaction on Monday, May 1st. The stock was sold at an average price of $68.60, for a total value of $85,750.00. Following the transaction, the chief financial officer now directly owns 62,783 shares of the company’s stock, valued at $4,306,913.80. The disclosure for this sale can be found here. Insiders sold a total of 173,121 shares of company stock valued at $13,007,522 over the last quarter. 1.97% of the stock is owned by corporate insiders.
ResMed Company Profile
ResMed Inc is a holding company. The Company is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease (COPD), neuromuscular disease and other diseases.
Receive News & Ratings for ResMed Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ResMed Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.